A 67-year-old man came to us carrying a word that changes everything the moment it is spoken: cancer. He had no dramatic story to tell. He felt well. There had been no pain, no obvious sign that anything was wrong. What brought him into this situation was a number, a routine PSA blood test that had crept upward, prompting a biopsy of the prostate. The biopsy came back positive, and from that point on he was a man with prostate cancer, and a surgery date.
It is worth pausing on how quietly this kind of diagnosis usually arrives, because it shapes everything that follows. Most low-risk prostate cancer causes no symptoms at all. It does not announce itself. It is found, not felt, which means a great many men go from feeling perfectly healthy to being a cancer patient on the strength of a lab result and a tissue sample.
If you have just been told you have prostate cancer and feel completely well, that contradiction is not a mistake. It is one of the defining features of the disease, and it matters for what you decide next.
A few things are worth understanding about this diagnosis before any decision is made:
- Early prostate cancer is usually silent, producing no symptoms whatsoever in its low-risk forms
- It is typically found through a rising PSA blood level rather than through how a man feels
- Urinary symptoms, when they exist, are often unrelated, caused by a benign enlarged prostate rather than the cancer
- Not all prostate cancers behave the same way, and the grade matters enormously
- The main risks for many men come from the treatment, including lasting incontinence and erectile dysfunction, not from the cancer itself
That final point is the one most often lost in the rush that follows the word cancer.
What the biopsy actually showed
His results placed him firmly in the lowest-risk category. The cancer was graded Gleason 6, which corresponds to ISUP grade group 1, the least aggressive grade that is routinely diagnosed. It was locally confined, sitting within the prostate, and there was no sign of it growing through the capsule or spreading beyond. In other words, this was the slowest, most contained version of the disease, the kind that in many men never goes on to cause harm within their lifetime.
The first recommendation
The first opinion came from urology, and it was decisive. Surgery was recommended, and a date for a radical prostatectomy, the complete removal of the prostate, was already being arranged.
When a patient hears "cancer," the instinct to remove it entirely is powerful, shared by patients and doctors alike. Cutting it out feels like the safe, definitive answer.
But there is a hidden cost in that instinct, and it is not small. A radical prostatectomy is major surgery, and even in expert hands it carries real risks of lasting urinary incontinence and erectile dysfunction. For a cancer this slow and this contained, the operation can do more damage to a man's daily life than the disease itself ever would. He was about to trade a silent, low-risk tumour for two side effects he would feel every single day.
The second opinion
Before the surgery went ahead, he sought a second opinion from uro-oncology, and the recommendation was strikingly different. Rather than operate, the advice was active surveillance, in line with the German S3 clinical guideline, which explicitly supports this approach for low-risk disease.
The phrase active surveillance is easy to misread, so it is worth being clear about what it is and is not:
- It is not ignoring the cancer or doing nothing
- It means watching it closely and deliberately, with regular PSA blood tests
- It includes repeat biopsies over time to check the cancer has not changed character
- It keeps every treatment option fully open, ready to act the moment there is any sign of progression
The whole logic is that you do not need to treat a slow, contained cancer today if you can reliably catch any change tomorrow. Treatment is held in reserve rather than abandoned.
He chose surveillance. Five years later, he has had no progression, no treatment, no incontinence and no erectile dysfunction. The cancer is still being watched, and it has still never needed a knife.
Why this case matters
The lesson here cuts against a deep instinct, which is exactly why it is so important.
Low-risk prostate cancer is widely regarded as one of the most over-treated diagnoses in all of oncology. The danger is not only the cancer. It is also the harm of treating a cancer that was never going to hurt you.
The word cancer carries such weight that it can short-circuit careful thinking. It pushes everyone toward action, because doing something feels responsible and watching feels passive. But for genuinely low-risk disease, the guidelines have shifted precisely because the data showed that aggressive treatment often left men worse off, burdened with permanent side effects for a tumour that posed little real threat. Oncological caution, taken too far, can itself become a source of harm.
A word of balance
This is not a message that prostate cancer is harmless or that surgery is wrong. Higher-grade and more advanced prostate cancers are serious and absolutely warrant decisive treatment, and surgery saves lives in those cases. Active surveillance also demands discipline, with a patient who will actually attend the monitoring, and it is not the right path for everyone. Some low-grade cancers do progress, which is the entire reason surveillance is active rather than passive. The point is narrower and more humane: a low-risk diagnosis deserves a genuine conversation about whether treatment is needed now, rather than an automatic march to the operating room.
A second opinion is especially worth seeking when:
- You have been recommended major cancer surgery for a tumour described as low-risk, low-grade or contained
- Active surveillance or less invasive options have not been clearly discussed with you
- The treatment's side effects could seriously affect your daily life, and you want to weigh them properly
- You feel rushed toward a surgery date before you have understood the full range of choices
Which leaves the question this case puts to all of us, and it is a genuinely hard one: when does the safe, cautious instinct to remove a cancer stop protecting the patient and start harming him instead?
Note: prostate cancer treatment decisions are highly individual, and this is one case rather than medical advice. If this resonates with your own situation, the right next step is a careful conversation with your own specialists.